- Synopsys halts China sales and services as new U.S. export rules take effect on May 29
- Synopsys pulls forecasts after U.S. bans chip software exports to China, revokes key licenses
- Get daily-updated rankings across momentum, growth, value, trends, and quality to spot the strongest stocks in any market.
Synopsys, Inc SNPS ordered its China employees to halt services and sales in the country effective May 29, 2025, after the new U.S. export restrictions kicked in, Reuters reported on Friday, citing an internal letter.
Products affected include semiconductor design software and chemicals.
This week, the U.S. ordered several companies to stop shipping goods to China without a license, and licenses, which had already been granted to specific suppliers, were revoked.
On Thursday, the company disclosed that it received a letter from the Bureau of Industry and Security of the U.S. Department of Commerce informing Synopsys of new export restrictions related to China and is ascertaining the potential impact. As a result, it suspended its third quarter outlook (Revenue $1.75 billion–$1.78 billion, Adj EPS $3.82-$3.87).
Also Read: Nvidia, Broadcom Lead Fund Manager Buys Even As Semiconductor Sector Cools: Analysts
The U.S. sanctions prompted Chinese companies, including Alibaba Group Holding BABA, to turn to China-made AI chips as U.S. export curbs cut Nvidia Corp NVDA supply.
Trending Investment Opportunities
Synopsys, Cadence Design Systems, Inc CDNS, and Siemens’ Mentor Graphics control over 70% of China’s electronic design automation (EDA) software market, which chipmakers can use to design semiconductors ranging from smartphones to computers and cars.
Synopsys stock lost over 19% in the last 12 months.
On Wednesday, Synopsys reported second-quarter revenue of $1.60 billion, which aligns with the consensus estimate. The adjusted EPS of $3.67 beat the street view of $3.38.
Price Action: SNPS shares are trading higher by 1.50% to $461.82 at last check Friday.
Read Next:
Image Via Shutterstock
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.